Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 OptiNoseMedicenna TherapeuticsscPharmaceuticalsNovanConcert Pharmaceuticals
SymbolNASDAQ:OPTNNASDAQ:MDNANASDAQ:SCPHNASDAQ:NOVNNASDAQ:CNCE
Price Information
Current Price$3.45$3.98$6.20$1.36$4.52
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.60.71.31.21.7
Analysis Score3.33.53.31.53.5
Community Score2.40.02.42.22.7
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.81.71.7
Earnings & Valuation Score0.60.00.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$18.00$10.00$12.33$1.50$20.50
% Upside from Price Target421.74% upside151.26% upside98.92% upside10.29% upside353.54% upside
Trade Information
Market Cap$186.37 million$215.00 million$178.08 million$224.45 million$147.04 million
Beta1.031.390.440.010.77
Average Volume452,776214,48597,17815,791,918494,197
Sales & Book Value
Annual Revenue$34.63 millionN/AN/A$4.90 million$1.08 million
Price / Sales5.27N/AN/A42.09134.65
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.48 per share$0.77 per share$2.76 per share($0.89) per share$4.26 per share
Price / Book2.33N/AN/A-1.531.06
Profitability
Net Income$-110,050,000.00$-6,220,000.00$-33,000,000.00$-30,640,000.00$-78,170,000.00
EPS($2.63)($0.19)($1.77)($0.80)($3.29)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-230.14%N/AN/A-379.35%-921.38%
Return on Equity (ROE)-294.64%-40.19%-44.04%N/A-55.20%
Return on Assets (ROA)-59.29%-37.66%-32.52%-43.81%-44.83%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio3.79%N/A0.21%0.11%N/A
Current Ratio3.98%26.75%16.07%5.56%18.51%
Quick Ratio3.76%26.75%16.07%5.56%18.51%
Ownership Information
Institutional Ownership Percentage62.93%3.90%62.53%6.23%69.68%
Insider Ownership Percentage38.00%N/A4.08%3.00%10.10%
Miscellaneous
Employees2047262470
Shares Outstanding52.95 million52.96 million27.36 million151.65 million32.17 million
Next Earnings Date5/6/2021 (Estimated)5/21/2021 (Estimated)5/11/2021 (Estimated)5/19/2021 (Estimated)4/29/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Given Consensus Rating of "Buy" by AnalystsConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - March 29 at 11:02 AM
Concert Pharmaceuticals Inc. [CNCE] moved down -5.08: Why It’s ImportantConcert Pharmaceuticals Inc. [CNCE] moved down -5.08: Why It’s Important
dbtnews.com - March 26 at 5:08 PM
KalVista Pharmaceuticals Appoints Nancy Stuart to Board of DirectorsKalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors
businesswire.com - March 19 at 8:10 AM
Concert Pharmaceuticals, Inc. (CNCE) Q4 2020 Earnings Call TranscriptConcert Pharmaceuticals, Inc. (CNCE) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 25 at 7:39 PM
Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical ProgramsConcert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs
finance.yahoo.com - February 25 at 8:20 AM
Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021
finance.yahoo.com - February 18 at 8:11 AM
CNCE Feb 2021 17.500 callCNCE Feb 2021 17.500 call
uk.finance.yahoo.com - February 11 at 6:29 PM
Mid-day market update: Silver surges 7%; Concert Pharmaceuticals (CNCE Stock) shares plungeMid-day market update: Silver surges 7%; Concert Pharmaceuticals (CNCE Stock) shares plunge
fxstreet.com - February 3 at 12:53 PM
Alopecia program takes center stage at Concert after schizophrenia failureAlopecia program takes center stage at Concert after schizophrenia failure
bioworld.com - February 1 at 11:30 PM
70 Stocks Moving In Mondays Mid-Day Session70 Stocks Moving In Monday's Mid-Day Session
msn.com - February 1 at 6:30 PM
Why Concert Pharmaceuticals Stock Cratered TodayWhy Concert Pharmaceuticals Stock Cratered Today
finance.yahoo.com - February 1 at 6:30 PM
Stock Alert: Concert Pharmaceuticals Tanks 40%Stock Alert: Concert Pharmaceuticals Tanks 40%
nasdaq.com - February 1 at 1:30 PM
Concert Pharmaceuticals Announces Results from CTP-692 Phase 2 Trial in Patients with SchizophreniaConcert Pharmaceuticals Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia
finance.yahoo.com - February 1 at 7:40 AM
Is CNCE A Good Stock To Buy Now?Is CNCE A Good Stock To Buy Now?
finance.yahoo.com - December 17 at 1:57 PM
How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
finance.yahoo.com - December 16 at 7:51 AM
News for Concert Pharmaceuticals IncNews for Concert Pharmaceuticals Inc
markets.businessinsider.com - December 5 at 7:01 AM
Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q3 2020 Results - Earnings Call TranscriptConcert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 6:04 AM
Concert Pharmaceuticals, Inc. (CNCE) Q3 2020 Earnings Call TranscriptConcert Pharmaceuticals, Inc. (CNCE) Q3 2020 Earnings Call Transcript
fool.com - November 6 at 4:13 PM
Concert: 3Q Earnings SnapshotConcert: 3Q Earnings Snapshot
chron.com - November 5 at 10:00 AM
Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company UpdateConcert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update
finance.yahoo.com - November 5 at 10:00 AM
Concert Pharmaceuticals, Inc. to Host Earnings CallConcert Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 5 at 10:00 AM
Concert Pharma launches late-stage study of CTP-543 in hair loss disorderConcert Pharma launches late-stage study of CTP-543 in hair loss disorder
seekingalpha.com - November 3 at 9:40 AM
Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia AreataConcert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
finance.yahoo.com - November 3 at 9:40 AM
If You Had Bought Concert Pharmaceuticals (NASDAQ:CNCE) Stock A Year Ago, You Could Pocket A 59% Gain TodayIf You Had Bought Concert Pharmaceuticals (NASDAQ:CNCE) Stock A Year Ago, You Could Pocket A 59% Gain Today
finance.yahoo.com - November 1 at 9:06 AM
Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV CongressConcert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress
finance.yahoo.com - October 29 at 2:46 PM
DateCompanyBrokerageAction
7/16/2020OptiNosePiper SandlerReiterated Rating
7/16/2020OptiNoseRoyal Bank of CanadaReiterated Rating
3/5/2020OptiNoseCantor FitzgeraldLower Price Target
12/18/2019OptiNoseCowenInitiated Coverage
8/13/2019OptiNoseBMO Capital MarketsLower Price Target
4/23/2019OptiNosePiper Jaffray CompaniesSet Price Target
12/17/2020Medicenna TherapeuticsOppenheimerInitiated Coverage
9/10/2020Medicenna TherapeuticsHC WainwrightInitiated Coverage
8/24/2020Medicenna TherapeuticsBrookline Capital ManagementReiterated Rating
8/24/2020Medicenna TherapeuticsBloom BurtonReiterated Rating
11/30/2020scPharmaceuticalsSVB LeerinkBoost Price Target
6/14/2018scPharmaceuticalsJefferies Financial GroupLower Price Target
3/29/2019NovanJMP SecuritiesDowngrade
2/2/2021Concert PharmaceuticalsTruistLower Price Target
12/16/2020Concert PharmaceuticalsBerenberg BankInitiated Coverage
10/2/2020Concert PharmaceuticalsMizuhoReiterated Rating
2/27/2020Concert PharmaceuticalsStifel NicolausDowngrade
1/22/2020Concert PharmaceuticalsSunTrust BanksReiterated Rating
9/30/2019Concert PharmaceuticalsJanney Montgomery ScottReiterated Rating
(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.